GSK Experimental Drug Achieves Functional Cure in 20% of Hepatitis B Patients
GlaxoSmithKline reported that an experimental hepatitis B treatment achieved a functional cure in approximately 20% of chronic hepatitis B patients in clinical trials, significantly exceeding the performance of existing treatments. A functional cure means patients achieve sustained control of the virus without ongoing therapy. The results represent a potential breakthrough in hepatitis B treatment, which affects approximately 2 million Americans and requires lifelong management under current standards of care. The drug remains in development with no immediate timeline for regulatory approval or market availability.
Medicaid managed care organizations cover a disproportionate share of hepatitis B patients and could face significant pharmacy cost and utilization changes if an effective cure receives FDA approval and becomes a covered benefit.
Pharmacy · Managed Care
You might also like